Phase III CREDENCE study of Invokana finds benefits for kidney function in diabetic nephropathy.- Janssen Pharma
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of an important new analysis from the landmark Phase III CREDENCE study, which found that Invokana (canagliflozin) consistently reduced the risk of renal and cardiovascular (CV) events in patients with various levels of kidney function, or estimated glomerular filtration rates (eGFR).
This analysis showed that Invokana provides a strong, consistent safety profile and efficacy at all tested eGFR levels. Specifically, greater renal absolute benefits were observed in those with the most advanced renal insufficiency (eGFR <60 ml min 1.73 m2). in this prespecified secondary analysis, credence researchers investigated whether the effects of invokana on clinically important outcomes were consistent across screening egfr levels. of the 4,401 patients enrolled, 1,313 (30 percent) had moderately to severely decreased kidney function (egfr 30 to><45 ml min 1.73 m2), 1,279 (29 percent) had mildly to moderately decreased kidney function (egfr 45 to><60 ml min 1.73 m2) and 1,809 (41 percent) had mildly decreased kidney function (egfr 60 to><90 ml min 1.73 m2).>90>60>45>60>
The results of the analysis were consistent with the primary study findings, with the following observations: Invokana consistently lowered the risk of CV and renal events in patients across all eGFR subgroups (all p-interaction >0.11). Canagliflozin led to fewer adverse events and serious adverse events overall, with consistent results across screening eGFR subgroups (p-interaction = 0.40 and 0.15, respectively). Invokana also reduced A1c, blood pressure, body weight, and albuminuria (protein in the urine) compared to placebo across all eGFR subgroups. Results from this secondary analysis were presented at the American Society of Nephrology (ASN) Kidney Week 2019 and build on the positive primary results from the Phase III CREDENCE study.
Related news and insights
AbbVie has announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (Skyrizi 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
Merck Inc., announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected by the end of the year.
Merck Inc., and Eisai announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted positive opinions recommending approval of the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima (marketed as Kisplyx in the European Union [EU]) for the treatment of advanced renal cell carcinoma [RCC]), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for two different indications.